{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:49:18Z","timestamp":1790851758088,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hospitalization significantly elevates venous thromboembolism (VTE) risk, yet optimal prophylactic anticoagulation remains debated. While low-molecular-weight heparin (LMWH) has long been the standard, direct oral anticoagulants (DOACs) like rivaroxaban offer oral administration without routine monitoring. We systematically reviewed 24 studies identified through PubMed and Web of Science (2010\u20132024), using predefined inclusion and exclusion criteria. Studies were screened, duplicates removed, and data extracted on efficacy, safety, cost-effectiveness, and patient-centered outcomes. High-risk subgroups, such as those with cancer or renal impairment were a focus of analysis. Efficacy: Rivaroxaban demonstrated non-inferiority to LMWH in VTE prevention, with superior postoperative thromboprophylaxis in orthopedic patients. Safety: Minor bleeding incidence was marginally higher with rivaroxaban, but major bleeding risk was comparable. Economics: Rivaroxaban reduced costs by approximately $1,200 per VTE patient, particularly in cancer-related cases. Rivaroxaban provides equally effective VTE prophylaxis with enhanced practicality (oral administration, no monitoring) and significant healthcare savings. Therapy selection should prioritize renal function, cancer status, and bleeding risk. Future research must address DOAC safety in severe renal\/hepatic impairment and optimize reversal-agent accessibility.<\/jats:p>","DOI":"10.3389\/fphar.2025.1652779","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:17:48Z","timestamp":1758773868000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism prophylaxis: a systematic review of efficacy, safety, and cost-effectiveness"],"prefix":"10.3389","volume":"16","author":[{"given":"Bin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12959-015-0051-3","article-title":"Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin\/vitamin K antagonist","volume":"13","author":"Bamber","year":"2015","journal-title":"Thromb. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1160\/TH16-06-0485","article-title":"Rivaroxaban real-world evidence: validating safety and effectiveness in clinical practice","volume":"116","author":"Beyer-Westendorf","year":"2016","journal-title":"Thromb. Haemost."},{"key":"B3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1160\/TH11-08-0565","article-title":"The treatment of venous thromboembolism with low-molecular-weight heparins: a meta-analysis","volume":"107","author":"Bochenek","year":"2012","journal-title":"Thromb. Haemost."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1016\/j.annemergmed.2013.07.306","article-title":"Treatment of pulmonary embolism with rivaroxaban and LMWH-VKA: length of stay and economic implications in the emergency department setting","volume":"62","author":"Bookhart","year":"2013","journal-title":"Ann. Emerg. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1586\/14779072.2013.845525","article-title":"Patient selection for thromboprophylaxis in medical inpatients","volume":"11","author":"Bozzato","year":"2013","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.1007\/s00520-022-07137-9","article-title":"Inpatient primary prophylaxis of cancer-associated thromboembolism (CAT)","volume":"30","author":"Butler","year":"2022","journal-title":"Support Care Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1055\/a-2259-0662","article-title":"Comparison of clinical outcomes in patients with active cancer receiving rivaroxaban or low-molecular-weight heparin: the OSCAR-UK study","volume":"125","author":"Cohen","year":"2024","journal-title":"Thromb. Haemost."},{"key":"B8","doi-asserted-by":"publisher","first-page":"11368","DOI":"10.1182\/blood-2022-166949","article-title":"Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism","volume":"140","author":"Coleman","year":"2022","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1182\/bloodadvances.2020002242","article-title":"Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism","volume":"4","author":"Costa","year":"2020","journal-title":"Blood Adv."},{"key":"B10","doi-asserted-by":"publisher","first-page":"A17715","DOI":"10.1161\/circ.132.suppl_3.15386","article-title":"Abstract 15386: hospitalizations and other healthcare resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight heparin and warfarin in the outpatient setting","volume":"132","author":"Deitelzweig","year":"2015","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.clinthera.2016.07.002","article-title":"Hospitalizations and other health care resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight heparin and warfarin in the outpatient setting","volume":"38","author":"Deitelzweig","year":"2016","journal-title":"Clin. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.3760\/cma.j.cn112137-20240604-01259","article-title":"Comparison of the efficacy of rivaroxaban versus low-molecular-weight heparin in the treatment of cancer-associated venous thromboembolism","volume":"104","author":"Dong","year":"2024","journal-title":"Chin. Med. J. Engl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"B14","first-page":"270","article-title":"Damned if you do, damned if you don\u2019t","volume":"13","author":"Ghimire","year":"2018","journal-title":"J. Hosp. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/europace\/euac020","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: a position paper from the esc working group on thrombosis, in collaboration with the European heart rhythm association, the association for acute CardioVascular care and the asia-pacific heart rhythm society","volume":"24","author":"Gorog","year":"2022","journal-title":"Europace."},{"key":"B16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/13696998.2017.1331912","article-title":"Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in The Netherlands","volume":"20","author":"Heisen","year":"2017","journal-title":"J. Med. Econ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtha.2023.09.020","article-title":"Anticoagulation in chronic kidney disease: current status and future perspectives","volume":"22","author":"Jones","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"B19","first-page":"A20228","article-title":"Healthcare resource utilization associated with venous thromboembolism in cancer patients treated with anticoagulants in a commercial insurance population","volume":"136","author":"Khorana","year":"2017","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1182\/blood-2019-128581","article-title":"Safety and effectiveness of rivaroxaban versus low molecular weight heparin for treatment of cancer-associated venous thrombosis: a SEER-Medicare-linked data analysis","volume":"134","author":"Kohn","year":"2019","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/14656566.2021.1879050","article-title":"Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom\u2014are changes on the horizon?","volume":"22","author":"Kotalczyk","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/1098612X211013736","article-title":"Dual therapy with clopidogrel and rivaroxaban in cats with thromboembolic disease","volume":"24","author":"Lo","year":"2022","journal-title":"J. Feline Med. Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/s0735-1097(16)32258-6","article-title":"Rivaroxaban compared to low molecular weight heparin in treatment of malignancy associated venous thromboembolism","volume":"67","author":"McBane","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3111\/13696998.2015.1096274","article-title":"Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH\/warfarin","volume":"19","author":"Merli","year":"2016","journal-title":"J. Med. Econ."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of Andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.mcna.2020.03.004","article-title":"Treatment of acute venous thromboembolism","volume":"104","author":"Nair","year":"2020","journal-title":"Med. Clin. N. Am."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1080\/13696998.2019.1668193","article-title":"Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting","volume":"22","author":"Nielsen","year":"2019","journal-title":"J. Med. Econ."},{"key":"B28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12471-021-01606-2","article-title":"Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events","volume":"29","author":"Olie","year":"2021","journal-title":"Neth Heart J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3111\/13696998.2014.1001850","article-title":"The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism","volume":"18","author":"Patel","year":"2015","journal-title":"J. Med. Econ."},{"key":"B31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/clinpract14010027","article-title":"Optimizing atrial fibrillation care: comparative assessment of anticoagulant therapies and risk factors","volume":"14","author":"Rus","year":"2024","journal-title":"Clin. Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"S320","DOI":"10.1016\/j.cjca.2016.07.554","article-title":"Understanding the optimization issues facing patients on anticoagulation therapy","volume":"32","author":"Sherrard","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.suc.2017.11.003","article-title":"New trends in anticoagulation therapy","volume":"98","author":"Smith","year":"2018","journal-title":"Surg. Clin. North Am."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1080\/13696998.2019.1620752","article-title":"Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants","volume":"22","author":"Streiff","year":"2019","journal-title":"J. Med. Econ."},{"key":"B35","first-page":"2865","article-title":"Thrombelastogram assesses anticoagulant clinical effect of rivaroxaban versus low molecular weight heparin after total hip arthroplasty","volume":"13","author":"Sun","year":"2020","journal-title":"Int. J. Clin. Exp. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3949\/ccjm.82a.140002","article-title":"Selecting antithrombotic therapy for patients with atrial fibrillation","volume":"82","author":"Tanaka-Esposito","year":"2015","journal-title":"Cleve Clin. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.15420\/ecr.2023.24","article-title":"Selection of non-vitamin K antagonist oral anticoagulant for stroke prevention in atrial fibrillation based on patient profile: perspectives from Vietnamese experts. Part 1","volume":"18","author":"Ton","year":"2023","journal-title":"Eur. Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.thromres.2023.10.015","article-title":"Application of the RIETE score to identify low-risk patients with pulmonary embolism: from the COMMAND VTE Registry","volume":"232","author":"Tsujisaka","year":"2023","journal-title":"Thromb. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehaa1097","article-title":"Patient-tailored antithrombotic therapy following percutaneous coronary intervention","volume":"42","author":"van der Sangen","year":"2021","journal-title":"Eur. Heart J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4717271","DOI":"10.1155\/2023\/4717271","article-title":"Global research hotspots in venous thromboembolism anticoagulation: a knowledge-map analysis from 2012 to 2021","volume":"2023","author":"Wang","year":"2023","journal-title":"J. Interv. Cardiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1373635","DOI":"10.3389\/fphar.2024.1373635","article-title":"Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study","volume":"15","author":"Wu","year":"","journal-title":"Front. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/10600280231178335","article-title":"Comparison of the efficacy and safety of rivaroxaban and low molecular heparin in preventing venous thromboembolism in inpatient cancer patients","volume":"58","author":"Wu","year":"","journal-title":"Ann. Pharmacother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e11384","DOI":"10.1097\/MD.0000000000011384","article-title":"Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: a meta-analysis","volume":"97","author":"Xing","year":"2018","journal-title":"Med. Baltim."},{"key":"B45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jjcc.2021.08.026","article-title":"Venous thromboembolism: recent advancement and future perspective","volume":"79","author":"Yamashita","year":"2022","journal-title":"J. Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12916-023-03069-1","article-title":"Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism","volume":"21","author":"Yoon","year":"2023","journal-title":"BMC Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1498692","DOI":"10.3389\/fpubh.2025.1498692","article-title":"Pharmacoeconomic evaluation of direct oral anticoagulants for cancer-associated thrombosis: a systematic review","volume":"13","author":"You","year":"2025","journal-title":"Front. Public Health"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1652779\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:17:50Z","timestamp":1758773870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1652779\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":47,"alternative-id":["10.3389\/fphar.2025.1652779"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1652779","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1652779"}}